中文摘要：

(HER2 ) 背景人的表皮的生长因素 2 是最重要的预言因素之一，但是仅仅乳癌病人 HER2 的 25%-30% 是积极的。是否有另外的分子的标记，能被用来预言在 HER2 否定 patients.This 学习的预后和复发与侵略乳癌在 281 个病人与临床的结果调查了 cyclin A2 和 HER2 层次的关联以便识别 cyclin A2 是否能在 HER2 用作一个预示的因素，是未知的染色的否定 patients.Methods Immunohistochemical 被用来在 281 个病人检测 cyclin A2 和 HER2 表示。Cyclin A2。并且 HER2 基因扩大在 12 个病人用基因分析和 RT-PCR 被分析。风险和幸存估计用木头等级， Kaplan-Meier，和考克斯回归分析被分析；有幸存的 cyclin A2 和 HER2 一致性与更高的 cyclin A2 用 Kappa analysis.Results 病人被分析， HER2 表情有显著地更短的没有疾病的幸存时期(P=0.047 和 P=0.05，分别地) 。Kappa 分析执行了那 cyclin A2， HER2 显示出一个低 Kappa 索引(kappa=0.37 ) ，允许我们断定 cyclin A2 和 HER2 检测不同病理。基因分析和 RT-PCR 证明 cyclin A2 是在有早恶化的病人的 upregulated；平均增加是 3.69-2.74 fold.Conclusions Cyclin A2， HER2 与增长和高复发被联系，特别地当联合时。Cyclin A2 被原子染色容易检测并且可能是为在 HER2 否定病人的复发风险的有用 biomarker。

英文摘要：

Background Human epidermal growth factor 2 （HER2） is one of the most important prediction factors, but only 25%-30% of breast cancer patients HER2 are positive. It is unknown whether there are other molecular markers that could be used to predict prognosis and recurrence in HER2 negative patients.This study investigated correlations of cyclin A2 and HER2 levels with clinical outcomes in 281 patients with invasive breast cancer in order to identify whether cyclin A2 can serve as a prognostic factor in HER2 negative patients. Methods Immunohistochemical staining was used to detect cyclin A2 and HER2 expression in 281 patients. Cyclin A2 and HER2 gene amplifications were analyzed using gene analysis and RT-PCR in 12 patients. Risk and survival estimates were analyzed using Log-rank, Kaplan-Meier, and Cox regression analysis; cyclin A2 and HER2 consistency with survival were analyzed using Kappa analysis. Results Patients with higher cyclin A2 and HER2 expressions had significantly shorter disease-free survival periods （P=0.047 and P=-0.05, respectively）. Kappa analysis performed that cyclin A2 and HER2 showed a low Kappa index （kappa=0.37）, allowing us to conclude that cyclin A2 and HER2 detect different pathologies. Gene analysis and RT-PCR showed that cyclin A2 was upregulated in patients with early relapse; the average increase was 3.69-2.74 fold. Conclusions Cyclin A2 and HER2 are associated with proliferation and high recurrence, particularly when combined. Cyclin A2 is easily detected by nuclear staining and might be a useful biomarker for recurrence risk in HER2 negative patients.